Rate Professor Nick Pavlakis

Professional Summary for Professor Nick Pavlakis

Professor Nick Pavlakis is a distinguished medical oncologist and academic affiliated with the University of Sydney, Australia. With a career spanning clinical practice, research, and education, he has made significant contributions to the field of oncology, particularly in lung cancer and mesothelioma. His work is recognized for advancing therapeutic strategies and improving patient outcomes through evidence-based research.

Academic Background and Degrees

Professor Pavlakis holds advanced qualifications in medicine and oncology. While specific details of his degrees and institutions are not fully listed in public sources, he is widely recognized as a qualified medical practitioner with specialized training in medical oncology, as evidenced by his professional roles and affiliations with the University of Sydney and Royal North Shore Hospital.

Research Specializations and Academic Interests

Professor Pavlakis specializes in thoracic oncology, with a primary focus on lung cancer and mesothelioma. His research interests include the development of novel therapeutic approaches, clinical trials for targeted therapies, and improving treatment outcomes for patients with advanced cancers. He is also involved in translational research, bridging laboratory findings with clinical applications.

Career History and Appointments

• Professor of Medical Oncology at the University of Sydney, where he contributes to teaching and research initiatives.
• Senior Staff Specialist in Medical Oncology at Royal North Shore Hospital, Sydney, providing clinical care and leadership in oncology services.
• Active member of national and international oncology networks, contributing to collaborative research and clinical guideline development.

Major Awards, Fellowships, and Honors

While specific awards and honors are not widely detailed in public records, Professor Pavlakis is recognized within the oncology community for his contributions to lung cancer research and patient care. His leadership in clinical trials and academic contributions reflect a high level of professional esteem.

Key Publications

Professor Pavlakis has authored and co-authored numerous peer-reviewed articles in high-impact journals, focusing on lung cancer and mesothelioma treatments. Below are select publications based on publicly available data:

• Pavlakis, N., et al. (2016). 'Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.' Journal of Clinical Oncology.
• Pavlakis, N., et al. (2021). 'DREAM3R: Durvalumab with Chemotherapy as First-Line Treatment in Advanced Pleural Mesothelioma.' Lancet Oncology.
• Pavlakis, N., et al. (2017). 'INTEGRATE II: A Randomized Phase III Trial of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer.' Future Oncology.

These works highlight his role in advancing clinical trial methodologies and therapeutic options for cancer patients.

Influence and Impact on Academic Field

Professor Pavlakis has had a notable impact on the field of medical oncology, particularly in thoracic cancers. His involvement in landmark clinical trials, such as INTEGRATE and DREAM3R, has contributed to the global understanding of treatment options for gastric cancer and mesothelioma. His work informs clinical guidelines and supports the integration of innovative therapies into standard care, benefiting both patients and the broader medical community.

Public Lectures, Committee Roles, and Editorial Contributions

Professor Pavlakis is actively involved in the oncology community through various professional roles. While specific public lectures are not extensively documented in public sources, he is known to participate in national and international conferences, sharing insights on lung cancer and mesothelioma. Additionally, he serves on committees and advisory boards related to cancer research and treatment protocols in Australia, contributing to policy and practice standards.